Evotec SE and Alloy Therapeutics, a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec’s antibody discovery platform. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partners-with-alloy-therapeutics-to-expand-its-antibody-discovery-platform-6010
Autobahn Labs and UCSF Announce Strategic Drug Discovery Collaboration
Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, today announced a strategic collaboration with the University of California San Francisco (UCSF). The organizations will partner to identify promising early science with significant therapeutic potential, forming jointly owned ventures to accelerate the translation of scientific ideas to novel therapeutics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/autobahn-labs-and-ucsf-announce-strategic-drug-discovery-collaboration-6012
Evotec achieves key milestones in its collaboration with Bristol Myers Squibb on targeted protein degradation
Evotec SE today announced that the Company has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-key-milestones-in-its-collaboration-with-bristol-myers-squibb-on-targeted-protein-degradation-6008
Evotec and Sartorius partner with start-up Curexsys on iPSC-based exosome approach
Evotec SE and the life science company Sartorius announced today that they have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology leader specialising in the emerging field of therapeutic exosomes. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sartorius-partner-with-start-up-curexsys-on-ipsc-based-exosome-approach-6006
Evotec publishes DDup 10 – Evotec’s transforming transcriptomics toxicology platform
The 10th edition is dedicated to our newly developed next generation transcriptomics toxicology platform, a truly translational project across different groups at Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-10—evotecs-transforming-transcriptomics-toxicology-platform-6004
Evotec and Rappta Therapeutics enter discovery and development partnership focused on oncology target
Evotec SE today announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-rappta-therapeutics-enter-discovery-and-development-partnership-focused-on-oncology-target-6002
Evotec presents growth drivers of "Autobahn to Cures" at Capital Markets Day
Recorded webcast now available Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-presents-growth-drivers-of-autobahn-to-cures-at-capital-markets-day-6000
Evotec and STORM Therapeutics leverage INDiGO platform to progress oncology project towards clinical studies
Evotec SE announced today that, as part of its ongoing collaboration with STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, STORM has selected STC-15 as a first-in-class development candidate. STORM will now use INDiGO, Evotec’s unique integrated, accelerated IND-enabling platform, to progress STC-15 towards an IND application in 2021. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-storm-therapeutics-leverage-indigo-platform-to-progress-oncology-project-towards-clinical-studies-5998
Evotec SE reports results for the first nine months of 2020 and provides corporate update
MULTIPLE NEW & EXTENDED DRUG DISCOVERY AND DEVELOPMENT ALLIANCES; VERY GOOD PROGRESS IN CO-OWNED PIPELINE; INCREASING MOMENTUM DESPITE DIFFICULT BUSINESS ENVIRONMENT; GUIDANCE FOR FULL-YEAR 2020 CONFIRMED; CAPACITY EXPANSION ON TRACK FOR SWIFT START TO 2021 Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-results-for-the-first-nine-months-of-2020-and-provides-corporate-update-5994
Evotec expands Oxfordshire site into a fully-integrated R&D centre named "Dorothy Crowfoot Hodgkin Campus"
Evotec SE today announced the expansion of the Company’s existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 biologists by the end of the year, will bring together all the key functions for cutting-edge and high-performance small molecule discovery and up to commercial development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-oxfordshire-site-into-a-fully-integrated-rd-centre-named-dorothy-crowfoot-hodgkin-campus-5996